跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Takeda Pharma A/S

首页临床试验发起方与机构Takeda Pharma A/S

Takeda Pharma A/S

ACTIVE

Delta Park 45, Vallensbæk Strand, Hovedstaden, 丹麦www.takeda.dkSubsidiary

别名:

shire denmark a/s

隶属于 Takeda Pharmaceuticals International AG

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

14

13 进行中

药物批准

75

批准总数

监管机构

4

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

2

14.3%

不适用

1

7.1%

试验状态分布

进行中（未招募）

13

92.9%

已完成

1

7.1%

相关临床试验

该机构主办的试验（14）

Roflumilast and cognition in memory-impaired elderly

May 201780 名受试者

Efficacy of Roflumilast and Montelukast in the treatment of severe uncontrolled asthma

进行中（未招募）

Sep 201260 名受试者

A human study to investigate the positive and negative effects of ointments containing roflumilast in patients suffering from a chronic inflammatory skinrash.

进行中（未招募）

A human study to investigate the positive and negative effects of ointments containing roflumilast or BYK321084 in patients suffering from a chronic scaly skin rash.

进行中（未招募）

Efficacy of Roflumilast and Montelukast in the treatment of severe uncontrolled asthma

进行中（未招募）

Jun 201260 名受试者

The trial investigates the effect of 500 µg roflumilast tablets once daily versus placebo on exacerbation rate and pulmonary function in patients with Chronic Obstructive Pulmonary Disease (COPD) who are treated with a fixed combination of long-acting ß2-agonists (LABA) and inhaled glucocorticosteroids (ICS). Additionally it provides data on safety and tolerability in COPD patients treated with a fixed combination of LABA and ICS.

进行中（未招募）

May 20113002 名受试者

The trial investigates the effect of 500 µg roflumilast tablets once dailyversus placebo on exacerbation rate and pulmonary function in patientswith Chronic Obstructive Pulmonary Disease (COPD) who are treatedwith a fixed combination of long-acting ß2-agonists (LABA) and inhaledglucocorticosteroids (ICS). Additionally it provides data on safety andtolerability in COPD patients treated with a fixed combination of LABAand ICS.

进行中（未招募）

May 20113002 名受试者

The trial investigates the effect of 500 µg roflumilast tablets once dailyversus placebo on exacerbation rate and pulmonary function in patientswith Chronic Obstructive Pulmonary Disease (COPD) who are treatedwith a fixed combination of long-acting ß2-agonists (LABA) and inhaledglucocorticosteroids (ICS). Additionally it provides data on safety andtolerability in COPD patients treated with a fixed combination of LABAand ICS.

进行中（未招募）

Mar 20113002 名受试者

第 1 页，共 2 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

13

药物批准

EMA

European Medicines Agency

14

药物批准

SFDA

Saudi Food and Drug Authority

11

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

37

药物批准

近期批准

VIPDOMET 12,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

VIPDOMET 12,5 MG/850 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Azilsartan Medoxomil Potassium Tablets

Azilsartan Medoxomil Potassium Tablets

NINLARO 3 mg Hard Capsule

ENTYVIO 300 mg powder for concentrate for solution for infusion

NINLARO 4 mg Hard Capsule

资讯

暂无资讯文章

本页目录

概览
相关临床试验14
药物批准75
资讯

返回机构列表